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Thiazolidinediones are ligands that bind to and activate the nuclear peroxisome
proliferator-activated receptor gamma. They are widely used as insulin
sensitizers for the treatment of type 2 diabetes. Several studies have implicated
the peroxisome proliferator-activated receptor gamma agonists rosiglitazone and
pioglitazone in inflammatory events. To assess the anti-inflammatory properties
of rosiglitazone, we investigated its effects on the molecular and cellular
inflammatory response induced by a carotid injury in the rat. Male Wistar rats
were randomized into a rosiglitazone-treated group (10 mg kg(-1) day(-1)) and a
control group (0.9% w/v NaCl). The drug or vehicle was administered by gavage for
7 days before carotid injury and for up to 21 days after injury. The inflammatory
markers p38 mitogen-activated protein kinase, cyclooxygenase 2, nuclear
factor-kappaB, and heat shock protein 47 and the influx and activity of cells in 
response to injury were measured. Rosiglitazone treatment significantly reduced
the expression of the inflammatory markers compared with control group. p38
mitogen-activated protein kinase and nuclear factor-kappaB started to decrease a 
few hours after injury, whereas cyclooxygenase 2 and heat shock protein 47
expression decreased 7 and 14 days, respectively, after injury. Rosiglitazone
also reduced neointima formation and inflammatory cell infiltration. In
conclusion, rosiglitazone negatively regulated the inflammatory events involved
in tissue repair at molecular and cellular levels. These results suggest that
rosiglitazone plays a protective role in inflammatory vascular diseases.
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